Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Upstream Bio, Inc.NASDAQ: UPB
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 31.8% from a year ago
Total equity stood at $304M at the end of Q1 FY2026, down 31.8% from a year earlier and down 10.5% from the prior quarter.
Context
- Total equity amounted to 95.6% of total assets at the end of Q1 FY2026, down 2.1 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -31.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 339.77M USD
- Year-over-year change
- -27.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 339.77M | -27.7% |
| FY2024 | 2024-12-31 | 469.85M | +481.6% |
| FY2023 | 2023-12-31 | (123.13M) | -16.0% |
| FY2022 | 2022-12-31 | (106.16M) | — |
Total Equity vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -31.8% is the 8th highest of 10, against a peer median of +18.1%.
- Total equity amounts to 95.6% of total assets for UPB, versus a peer median of 87.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.05B USD | +131.1% | +142.3% | 95.6% | |
| Jun 2026 | $890.01M USD | +33.7% | -15.8% | 92.0% | |
| Sep 2026 | $753.74M USD | +127.0% | -3.6% | 95.8% | |
| Mar 2026 | $620.94M USD | -20.4% | -18.4% | 81.8% | |
| Mar 2026 | $511.73M USD | +197.9% | — | 87.7% | |
| Mar 2026 | $335.83M USD | +18.1% | — | 44.9% | |
UPBUpstream Bio, Inc. | Mar 2026 | $304M USD | -31.8% | — | 95.6% |
| Sep 2026 | €264.97M EUR | -15.1% | +22.0% | 89.8% | |
| Mar 2026 | $41.62M USD | -80.6% | -48.3% | 8.8% | |
| Mar 2026 | -$144.76M USD | -91.4% | — | 13.9% | |
| Peer median (excluding UPB) | — | +18.1% | -9.7% | 87.7% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.